Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
6
×
boston top stories
clinical trials
6
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
biotech
deals
fda
new york
san diego blog main
san diego top stories
abbvie
alexion pharmaceuticals
boston
bristol-myers squibb
drugs
intercept pharmaceuticals
nonalcoholic steatohepatitis
obeticholic acid
patisiran
pfizer
san francisco blog main
san francisco top stories
4d molecular therapeutics
acne
acorda therapeutics
agenus
akcea therapeutics
allergan
alnylam pharmaceuticals
ampyra
amyotrophic lateral sclerosis (als)
anylam pharmaceuticals
apokyn
apomorphine
astrazeneca
auris health
What
disease
6
×
drug
6
×
approved
fda
medicines
fatty
known
liver
nash
new
patients
pharma
pharmaceuticals
stop
treatment
acorda
ago
akcea
alnylam
alternative
amyloidosis
attr
autoimmune
available
battle
bio
candidate
caught
causing
companies
cope
data
deal
debilitating
dicerna
digital
epidemic
episodes
expensive
eye
Language
unset
Current search:
disease
×
drug
×
" boston blog main "
×
" clinical trials "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms